CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF
Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.
1 . A controlled-release composition, comprising
a plurality of controlled-release subunits,
wherein each controlled-release subunit comprises
an active agent subunit comprising carvedilol and a pharmaceutical excipient, and
a release-retarding coating substantially surrounding the active agent subunit;
wherein the carvedilol is present in an amount of less than about 59.4 mg free base equivalent.
2 . The controlled-release composition of claim 1 , wherein the controlled-release composition when administered to a patient in a non-fasted state is bioequivalent to the controlled-release composition when administered to a patient in a fasted state.
3 . The controlled-release composition of claim 1 , wherein the carvedilol is carvedilol free base, carvedilol benzoate, carvedilol citrate, carvedilol glutarate, carvedilol hydrobromide, carvedilol hydrochloride, carvedilol phosphate, carvedilol hydrogen phosphate, carvedilol dihydrogen phosphate, carvedilol lactate, carvedilol mandelate, carvedilol maleate, carvedilol mesylate, carvedilol oxalate, carvedilol sulfate, or a hydrate, solvate, polymorph, or non-crystalline form of the foregoing.
4 . The controlled-release composition claim 1 , wherein the carvedilol is carvedilol dihydrogen phosphate hemihydrate.
5 . The controlled-release composition claim 1 , wherein the carvedilol is present in an amount of about 70 mg carvedilol dihydrogen phosphate hemihydrate.
6 . The controlled-release composition of claim 1 , wherein the release-retarding coating material is a water insoluble alkyl cellulose; a methacrylic acid copolymer; a copolymer of acrylic and methacrylic acid; a methacrylic acid-methyl methacrylate copolymer; a methacrylic acid-ethyl acrylate copolymer; or a combination comprising at least one of the foregoing materials.
7 . The controlled-release composition of claim 1 , wherein the release-retarding coating material is ethyl cellulose, a methacrylic acid-methyl methacrylate copolymer, a methacrylic acid-ethyl acrylate copolymer, or a combination comprising at least one of the foregoing materials.
8 . The controlled-release composition of claim 1 , wherein each controlled-release subunit independently comprises a release-retarding coating material of ethyl cellulose, a methacrylic acid-methyl methacrylate copolymer, a methacrylic acid-ethyl acrylate copolymer, or a combination comprising at least one of the foregoing materials.
9 . The controlled-release composition of claim 1 , wherein each controlled-release subunit independently comprises a release-retarding coating material in an amount of about 2 to about 40 weight percent coat weight.
10 . The controlled-release composition of claim 1 , comprising a first plurality of controlled-release subunits comprising an ethyl cellulose coating present in an amount of about 6 to about 20 weight percent coat weight; and
a second plurality of controlled-release subunits comprising an ethyl cellulose coating present in an amount of about 14 to about 30 weight percent coat weight;
and optionally wherein the ethyl cellulose coating further comprises a water-soluble component.
11 . The controlled-release composition of claim 10 , wherein the first plurality of controlled-release subunits comprises about 25 to about 70 mg carvedilol dihydrogen phosphate hemihydrate; and
wherein the second plurality of controlled-release subunits comprises about 5 to about 50 mg carvedilol dihydrogen phosphate hemihydrate.
12 . The controlled-release composition of claim 10 , wherein the composition further comprises a third plurality of controlled-release subunits, or a plurality of immediate-release subunits comprising carvedilol and a pharmaceutical excipient.
13 . The controlled-release composition of claim 11 , wherein the first plurality of controlled-release subunits comprises about 55 mg carvedilol dihydrogen phosphate hemihydrate, and about 10 to about 18 weight percent ethyl cellulose coating; and
wherein the second plurality of controlled-release subunits comprises about 15 mg carvedilol dihydrogen phosphate hemihydrate, and about 18 to about 26 weight percent ethyl cellulose coating.
14 . The controlled-release composition of claim 1 , comprising a first plurality of controlled-release subunits comprising an ethyl cellulose coating present in an amount of about 10 to about 18 weight percent coat weight; and
a second plurality of controlled-release subunits comprising methacrylic acid-ethyl acrylate copolymer 1:1 coating present in an amount of about 2 to about 20 weight percent coat weight.
15 . The controlled-release composition of claim 14 , wherein the first plurality of controlled-release subunits comprises about 20 to about 70 mg carvedilol dihydrogen phosphate hemihydrate; and wherein the second plurality of controlled-release subunits comprises about 5 to about 55 mg carvedilol dihydrogen phosphate hemihydrate.
16 . The controlled-release composition of claim 15 , wherein the first plurality of controlled-release subunits comprises about 25 mg carvedilol dihydrogen phosphate hemihydrate, and about 12 to about 16 weight percent ethyl cellulose coating; and
wherein the second plurality of controlled-release subunits comprises about 45 mg carvedilol dihydrogen phosphate hemihydrate, and about 4 to about 10 weight percent methacrylic acid-ethyl acrylate copolymer 1:1 coating.
17 . The controlled-release composition of claim 1 , wherein the controlled-release subunits have a mean diameter of about 1000 to about 3000 micrometers.
18 . The controlled-release composition of claim 1 , wherein the composition further comprises a plurality of immediate-release subunits comprising carvedilol and a pharmaceutical excipient.
19 . The controlled-release composition of claim 1 , wherein the composition is a plurality of subunits in a capsule or a plurality of subunits in a tablet.
20 . The controlled-release composition of claim 1 , wherein the composition is bioequivalent to a reference drug according to New Drug Application No. 022012.
21 . The controlled-release composition of claim 1 , wherein the composition exhibits
a ratio of a geometric mean of logarithmic transformed AUC 0−∞ of the composition to a geometric mean of logarithmic transformed AUC 0−∞ of reference drug (New Drug Application No. 022012) of about 0.80 to about 1.25;
a ratio of a geometric mean of logarithmic transformed AUC 0−t of the composition to a geometric mean of logarithmic transformed AUC 0−t of reference drug (New Drug Application No. 022012) of about 0.80 to about 1.25;
a ratio of a geometric mean of logarithmic transformed C max of the composition to a geometric mean of logarithmic transformed C max of reference drug (New Drug Application No. 022012) of about 0.70 to about 1.43; or
a ratio of a geometric mean of logarithmic transformed C max of the composition to a geometric mean of logarithmic transformed C max of reference drug (New Drug Application No. 022012) of about 0.80 to about 1.25.
22 . A method of treating hypertension, congestive heart failure, or angina comprising administering a controlled-release composition of claim 1 .
23 . A controlled-release composition, comprising
a plurality of controlled-release subunits,
wherein each controlled-release subunit comprises
an active agent subunit comprising carvedilol and a pharmaceutical excipient, and
a release-retarding coating substantially surrounding the active agent subunit;
wherein the controlled-release composition exhibits substantially no food effect.
24 . The controlled-release composition of claim 23 , wherein the controlled-release composition when administered to a patient in a non-fasted state is bioequivalent to the controlled-release composition when administered to a patient in a fasted state.
25 . The controlled-release composition of claim 23 , wherein the carvedilol is carvedilol free base, carvedilol benzoate, carvedilol citrate, carvedilol glutarate, carvedilol hydrobromide, carvedilol hydrochloride, carvedilol phosphate, carvedilol hydrogen phosphate, carvedilol dihydrogen phosphate, carvedilol lactate, carvedilol mandelate, carvedilol maleate, carvedilol mesylate, carvedilol oxalate, carvedilol sulfate, or a hydrate, solvate, polymorph, or non-crystalline form of the foregoing.
26 . The controlled-release composition claim 23 , wherein the carvedilol is carvedilol dihydrogen phosphate hemihydrate.
27 . The controlled-release composition of claim 23 , wherein the release-retarding coating material is a water insoluble alkyl cellulose; a methacrylic acid copolymer; a copolymer of acrylic and methacrylic acid; a methacrylic acid-methyl methacrylate copolymer; a methacrylic acid-ethyl acrylate copolymer; or a combination comprising at least one of the foregoing materials.
28 . The controlled-release composition of claim 23 , wherein each controlled-release subunit independently comprises a release-retarding coating material in an amount of about 2 to about 40 weight percent coat weight.
29 . The controlled-release composition of claim 23 , comprising a first plurality of controlled-release subunits comprising an ethyl cellulose coating present in an amount of about 6 to about 20 weight percent coat weight, and optionally wherein the ethyl cellulose coating further comprises a water-soluble component; and
a second plurality of controlled-release subunits comprising a methacrylic acid-methyl methacrylate copolymer coating present in an amount of about 4 to about 20 weight percent coat weight.
30 . The controlled-release composition of claim 29 , wherein the first plurality of controlled-release subunits comprises about 45 to about 75 mg carvedilol dihydrogen phosphate hemihydrate; and
wherein the second plurality of controlled-release subunits comprises about 5 to about 35 mg carvedilol dihydrogen phosphate hemihydrate.
31 . The controlled-release composition of claim 29 , wherein the composition further comprises a third plurality of controlled-release subunits, or a plurality of immediate-release subunits comprising carvedilol and a pharmaceutical excipient.
32 . The controlled-release composition of claim 29 , wherein the first plurality of controlled-release subunits comprises about 60 mg carvedilol dihydrogen phosphate hemihydrate, and about 10 to about 18 weight percent ethyl cellulose coating; and
wherein the second plurality of controlled-release subunits comprises about 20 mg carvedilol dihydrogen phosphate hemihydrate, and about 8 to about 16 weight percent methacrylic acid-methyl methacrylate copolymer coating.
33 . The controlled-release composition of claim 23 , wherein the controlled-release subunits have a mean diameter of about 1000 to about 3000 micrometers.
34 . The controlled-release composition of claim 23 , wherein the composition further comprises a second plurality of controlled-release subunits, or a plurality of immediate-release subunits comprising carvedilol and a pharmaceutical excipient.
35 . The controlled-release composition of claim 23 , wherein the composition is a plurality of subunits in a capsule or a plurality of subunits in a tablet.
36 . The controlled-release composition of claim 23 ,
wherein the controlled-release composition exhibits a ratio of a geometric mean of logarithmic transformed AUC 0−∞ of the composition administered in a non-fasted state to a geometric mean of logarithmic transformed AUC 0−∞ of the composition administered in a fasted state of about 0.80 to about 1.25;
wherein the controlled-release composition exhibits a ratio of a geometric mean of logarithmic transformed AUC 0−t of the composition administered in a non-fasted state to a geometric mean of logarithmic transformed AUC 0−∞ T of the composition administered in a fasted state of about 0.80 to about 1.25; or
wherein the composition exhibits a ratio of a geometric mean of logarithmic transformed C max of the composition administered in a non-fasted state to a geometric mean of logarithmic transformed geometric mean C max of the composition administered in a fasted state of about 0.80 to about 1.25.
37 . A method of treating hypertension, congestive heart failure, or angina comprising administering a controlled-release composition of claim 23 .
38 . A controlled-release composition, comprising
a plurality of controlled-release subunits,
wherein each controlled-release subunit comprises
an active agent subunit comprising carvedilol dihydrogen phosphate hemihydrate and a pharmaceutical excipient, and
a release-retarding coating substantially surrounding the active agent subunit;
wherein the controlled-release composition exhibits reduced food effect when administered to a patient in a non-fasted state relative to the reference drug product, 80 mg of New Drug Application No. 022012.
39 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a single phase release (single T max ) within the first 4 hours after oral administration with or without food to a patient.
40 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a single phase release (single T max ) within the first 10 hours after oral administration with or without food to a patient.
41 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a first peak plasma T max1 of less than 4 hours, and a second peak plasma T max2 of greater than 10 hours after oral administration with or without food to a patient.
42 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a first peak plasma T max1 of less than 4 hours, and a second peak plasma T max2 of less than 10 hours after oral administration with or without food to a patient.
43 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a first peak plasma T max1 of greater than 4 hours, and a second peak plasma T max2 of greater than 10 hours after oral administration with or without food to a patient.
44 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a first peak plasma T max1 of greater than 4 hours, and a second peak plasma T max2 of less than 10 hours after oral administration with or without food to a patient.
45 . The controlled-release composition of claim 1 or 23 , wherein the controlled-release composition exhibits a first peak plasma T max1 of less than 4 hours, a second peak plasma T max2 of greater than 4 hours, and optionally a third peak plasma T max3 of greater than 4 hours after oral administration with or without food to a patient.